Roche's Partners: Replacing, or Fuelling In-House R&D?
Executive Summary
Partnering is a must for every drug firm these days. But Roche's reputation as a committed, yet hands-off development partner--forged in its relationship with Genentech--still sets it apart. Critics accuse the Swiss group of using partners to fill the gap in its own R&D; indeed, much of Roche's recent growth has come from others' drugs. Roche executives argue that you can't spot winners outside without a strong internal engine; that engine remains unproven. But point isn't whether Roche's own R&D is strong or weak. The point is, does it matter?
You may also be interested in...
The Rise of Regional Dealmaking
Biotechs' drive to retain a bigger chunk of downstream rights is forcing product-hungry Big Pharma to accept non-global licensing deals. They'll be up against existing regional players, more accustomed to sharing rights and prioritizing others' drugs.
At JPMorgan XXIV: Mostly Pharma but Little Strategic Agreement
The diversity of messages from the Big Pharma presenters at this important conference reflected the broader investment uncertainty about the sector. Investors weren't certain about the biotech business model either, though they packed the rooms. Among the basic arguments: whether the returns from companies pursuing compounds against novel targets will trump the returns from those companies pursuing precedented mechanisms.
The Buzz at JP Morgan--Biopharma: New Models Wanted
Perhaps the loudest message from the biopharmaceutical side of the JP Morgan conference was: "Change the Big Pharma model." The theme was pervasive-in discussions of the most interesting products; among the biotechs; indeed in the Big Pharma presentations themselves.